Aneel K Aggarwal

Aneel K. Aggarwal is a Professor in Pharmacological Sciences and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. His research focuses on understanding protein-nucleic acid interactions in cellular development and disease, particularly cancer. He holds an Endowed Chair in Structural Biology and has affiliations at the laboratory website http://www.protdnarna.org. His office is located at the Icahn (East) Building, Floor 16, Room 16-20C in New York, NY.

Dr. Aggarwal earned his PhD from King’s College, University of London. His work integrates structural biology, biochemistry, and molecular biology to study DNA repair mechanisms, DNA replication fidelity, and transcription/translation regulation. Notably, he investigates how DNA polymerases bypass damage during replication and their roles in cancer development.

His research interests span DNA repair, replication, transcription factors, translation, and structural biology. Key projects include studying enzymes’ specificity modulation, epigenetic regulators in bacteria, and mechanisms underlying signal-induced transcription. He employs cryo-EM, NMR, and small-angle scattering techniques to visualize molecular interactions.

Publications highlight a focus on cancer mechanisms, viral biology, and enzyme structural studies, with recent work on CBASS immune pathways, eRNA checkpoints, and WDR5 inhibitors for pancreatic cancer. His research trends emphasize translational applications for therapeutic development alongside fundamental biology.

• Dean’s Award for Excellence in Basic Science Research (2012)
• Faculty Council Award for Academic Excellence (2010)
• Mount Sinai Professor in Structural Biology (Endowed Chair) (2007)
• Doctor Harold and Golden Lamport Award (1995)
• Irma T. Hirschl Career Scientist Award (1990)

His advising and grants sections remain sparse in the provided text, though his research is supported by numerous awards. Collaborations include studies on influenza virus receptor specificity, Zika virus methyltransferases, and anti-pause enhancers in transcription. Industry relationships are noted, though specific details are not disclosed.